Eli Lilly CEO's Comments on Foundayo Spark Optimism Among Investors

Eli Lilly (LLY) stock has risen over 18% since April 30, outperforming the S&P 500 index. The surge follows positive remarks from CEO David Ricks about their new FDA-approved weight loss drug, Foundayo.

By Eric Volkman, The Motley Fool Mon, June 1, 2026 at 9:03 PM GMT+3 3 min read · Yahoo Finance · June 1, 2026, 18:03 UTC

Eli Lilly CEO's Comments on Foundayo Spark Optimism Among Investors

Tickers: $LLY $NVDA

Topics: CEO commentary Eli Lilly FDA approval Foundayo stock price movement Zepbound

Read the full article at Yahoo Finance

More World news

Suburban Propane Partners Outlines $60M-$70M Capital Expenditures for Fiscal 2027 Seeking Alpha · November 12, 2026, 17:00 UTC
Nvidia, Supermicro, and Megaspeed Face U.S. Department of Justice Probes Seeking Alpha · November 12, 2026, 17:00 UTC
Starbucks Implements Quarterly Performance-Based Bonuses for Baristas Seeking Alpha · November 12, 2026, 17:03 UTC
Jim Cramer Analyzes Nvidia Leadership Transition and Recommends AMD, Constellation Brands, and Kimberly-Clark CNBC · November 12, 2026, 16:55 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Threatening $500 Billion AI Financing Plan CNBC · November 12, 2026, 16:55 UTC
Al Mouj Muscat Receives Three Architectural Awards at International and Arabian Property Awards 2026 PR Newswire · November 12, 2026, 17:01 UTC
SoftBank Reports $7.1 Billion Quarterly Loss Driven by Natural Gas Turbine Over-Ordering TechCrunch · November 12, 2026, 17:00 UTC
PayPal and Kiva Renew Long-Term Partnership to Support Global Microloans PR Newswire · November 12, 2026, 17:00 UTC
Tesla to Discontinue Cybertruck Production by Summer 2027 to Prioritize Cybercab The Verge · November 12, 2026, 17:00 UTC
Absci Reports Q3 2026 Financial Results and Clinical Updates for ABS-201 Motley Fool · November 12, 2026, 16:54 UTC